natgillin/translations-raw huggingface dataset:
Bleeding risk is increased with concomitant administration of fondaparinux and agents that may enhance the risk of haemorrhage (see section 4.4). 
Tveganje krvavitve se poveča pri sočasni uporabi fondaparinuksa in učinkovin, ki lahko povečajo tveganje za krvavitev (glejte poglavje 4.4).
In post marketing experience, rare cases of gastritis, constipation, diarrhoea and bilirubinaemia have been reported. 
Med obdobjem trženja so bili opisani redki primeri gastritisa, zaprtosti, driske in bilirubinemije.
Disposal of syringes: 
Odstranjevanje injekcijskih brizg:
Thus, fondaparinux is not expected to interact with other medicinal products in vivo by inhibition of CYP-mediated metabolism. 
Zato ni pričakovati, da bi fondaparinuks medsebojno deloval z drugimi zdravili in vivo z zaviranjem metabolizma preko CYP.
Fondaparinux should be used with care in these patients. 
Pri teh bolnikih je treba fondaparinuks previdno uporabljati.
Treatment of ST segment elevation myocardial infarction (STEMI) in adults who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy. 
Zdravljenje miokardnega infarkta z dvigom segmenta ST (STEMI; “ST segment elevation myocardial infarction” pri odraslih , ki so prejeli trombolitik ali bolnikih, pri katerih v začetku ni bila izvedena druga oblika reperfuzijskega zdravljenja.
Patients were excluded if they had severe hepatic impairment, severe renal impairment (creatinine clearance <30ml/min), low body weight (<50kg), active cancer, symptomatic PE or a recent history of DVT/PE (<6 months) or superficial-vein thrombosis (<90 days), or superficial-vein thrombosis associated with sclerotherapy or a complication of an IV line, or they were at high risk of bleeding. 
Bolniki so bili izključeni, če so imeli hudo okvaro jeter, hudo okvaro ledvic (očistek kreatinina < 30 ml/min), majhno telesno maso (< 50 kg), aktivnega raka, simptomatsko pljučno embolijo ali nedavno anamnezo globoke venske tromboze/pljučne embolije (< 6 mesecev) ali povrhnje venske tromboze (< 90 dni) ali povrhnjo vensko trombozo, povezano s skleroterapijo ali kot zaplet intravenske linije, ali če so imeli veliko tveganje krvavitve.
Insert the full length of the needle at right angles into the skin fold (picture D). 
Celotno dolžino injekcijske igle zabodite v kožno gubo pod pravim kotom (slika D).
Fondaparinux doses above the recommended regimen may lead to an increased risk of bleeding. 
Odmerki fondaparinuksa, ki so večji od priporočene sheme odmerjanja, lahko povečajo tveganje za krvavitve.
A randomised, double blind, clinical trial (CALISTO) included 3002 patients with acute symptomatic isolated, spontaneous superficial-vein thrombosis of the lower limbs, at least 5 cm long, confirmed by compression ultrasonography. 
Opravljeno je bilo randomizirano, dvojno slepo klinično preskušanje (CALISTO), ki je zajelo 3002 bolnika z akutno, simptomatsko, izolirano spontano povrhnjo vensko trombozo spodnjih udov, dolgo vsaj 5 cm in potrjeno s kompresijskim ultrazvočnim pregledom.
Following once daily dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC. 
Po odmerjanju enkrat na dan je stanje dinamičnega ravnovesja v plazmi doseženo po 3 do 4 dneh, z 1,3-kratnim povečanjem Cmax in AUC.
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in adultsfor whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1). 
Zdravljenje nestabilne angine pektoris ali miokardnega infarkta brez dviga segmenta ST (UA/NSTEMI; “unstable angina/non-ST segment elevation myocardial infarction”) pri odraslih , pri katerih ni indicirano urgentno (< 120 minut) invazivno zdravljenje (PCI) (glejte poglavji 4.4 in 5.1).
• Prevention of VTE - Fondaparinux is known to be mainly excreted by the kidney. 
• Preprečevanje VTE - Znano je, da se fondaparinuks izloča predvsem preko ledvic.
In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group. 
V veliki podskupini bolnikov, ki so bili operirani zaradi tumorja (69 % vključenih bolnikov) je bila pojavnost VTE 4,7 % pri bolnikih, ki so prejemali fondaparinuks in 7,7 % pri bolnikih, ki so prejemali dalteparin.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days 
Preprečevanje venskih trombemboličnih dogodkov (VTE) pri bolnikih po velikih ortopedskih operacijah spodnjih okončin, ki so se zdravili do 9 dni
Patients who required thrombolysis or embolectomy or vena cava filter were excluded. 
Bolnike, pri katerih so bili potrebni tromboliza ali embolektomija ali filter v veni kavi, so izključili.
• Arixtra is given by injection under the skin (subcutaneously) into a skin fold of the lower abdominal area. 
• Zdravilo Arixtra si injicirajte pod kožo (subkutano), v kožno gubo v spodnjem predelu trebuha.
Rare: hypotension 
Redki: hipotenzija
Treatment should be initiated as soon as possible following diagnosis and continued for up to a maximum of 8 days or until hospital discharge if that occurs earlier. 
Zdravljenje lahko traja največ 8 dni ali do odpusta iz bolnišnice, če je bolnik odpuščen prej kot v 8 dneh.
• low number of red blood cells (anaemia) 
• zmanjšanje števila rdečih krvnih celic (anemija);
Fondaparinux also significantly reduced the rate of adjudicated fatal PE [0 patients (0.0%) vs 5 patients (1.2%), respectively]. 
Fondaparinuks je tudi signifikantno zmanjšal pogostost pripisane smrtne PE [0 bolnikov (0,0 %) proti 5 bolnikom (1,2 %)].
In an open-label study, 24 paediatric patients (n=10, age 1 to ≤ 5 years weight range 8-20 kg; n=7, age 6 to ≤ 12 years weight range 17-47 kg and n=7 age 13 to ≤ 18 years weight range 47-130 kg) diagnosed with venous thrombosis at study entry were administered fondaparinux. 
V odprti študiji je 24 pediatričnih bolnikov z diagnosticirano vensko trombozo ob vstopu v študijo (n = 10, starost od 1 do ≤ 5 let, razpon telesne mase 8-20 kg, n = 7, starost od 6 do ≤ 12 let, razpon telesne mase 17-47 kg in n = 7, starost od 13 do ≤ 18 let, razpon telesne mase 47-130 kg) prejelo fondaparinuks.
To avoid the loss of medicinal product when using the pre-filled syringe do not expel the air bubble from the syringe before the injection. 
Da bi preprečili izgubo zdravila, pri uporabi napolnjene injekcijske brizge, pred injiciranjem iz brizge ne odstranjujte zračnih mehurčkov.
In the Phase III UA/NSTEMI study, the most commonly reported non-bleeding adverse events (reported in at least 1% of subjects on fondaparinux) were headache, chest pain and atrial fibrillation. 
V študiji III. faze UA/NSTEMI so najpogosteje poročali o naslednjih neželenih učinkih, ki niso bili povezani s krvavitvami (poročila pri najmanj 1 % oseb, ki so prejemale fondaparinuks): glavobol, bolečina v prsih in atrijska fibrilacija.
Between 50 kg and 100 kg 
5 mg enkrat na dan od 50 kg do 100 kg
Following once daily subcutaneous dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC. 
Po subkutanem odmerku enkrat na dan je stanje dinamičnega ravnovesja v plazmi doseženo po 3 do 4 dneh, z 1,3-kratnim povečanjem Cmax in AUC.
Take special care with Arixtra: 
Bodite posebno pozorni pri uporabi zdravila Arixtra:
METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous or intravenous use Read the package leaflet before use. 
Subkutana ali intravenska uporaba Pred uporabo preberite priloženo navodilo.
Adverse reactions in medical patients 
Neželeni učinki pri internističnih bolnikih
The safety of fondaparinux 2.5 mg has been evaluated in 3,595 patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days, in 327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis of 1 week, 1,407 patients undergoing abdominal surgery treated up to 9 days, and in 425 medical patients who are at risk for thromboembolic complications treated up to 14 days. 
Varnost fondaparinuksa 2,5 mg so ocenjevali pri 3.595 bolnikih po veliki ortopedski operaciji na spodnjih okončinah, ki so se zdravili do 9 dni, pri 327 bolnikih po operaciji zaradi zloma kolka, ki so po začetni enotedenski profilaksi prejemali zdravilo še 3 tedne, 1.407 bolnikih po opravljenem kirurškem posegu v trebušni votlini, ki so se zdravili do 9 dni in pri 425 internističnih bolnikih s tveganjem trombemboličnih zapletov, zdravljenih do 14 dni dolgo.
Below 50 kg 
Običajni odmerek manjša od 50 kg
Syringe with a manual needle protection system Picture 2. 
Injekcijska brizga z ročnim sistemom za zaščito igle Slika 2.
For treatment of UA/NSTEMI and STEMI-Fondaparinux should be used with caution in patients who are being treated concomitantly with other agents that increase the risk of haemorrhage (such as GPIIb/IIIa inhibitors or thrombolytics). 
Pri zdravljenju UA/NSTEMI in STEMI, je treba fondaparinuks uporabljati previdno pri bolnikih, ki se sočasno zdravijo z drugimi zdravili, ki povečajo tveganje za krvavitve (kot so zaviralci GPIIb/IIIa ali trombolitiki).
Fondaparinux was administered at an initial dose of 0.1 mg/kg subcutaneously once daily and dosing was adjusted to achieve peak fondaparinux sodium concentrations of 0.5 to 1 mg/L after 4 hours. 
Fondaparinuks je bil uporabljen v začetnem odmerku 0,1 mg/kg subkutano enkrat na dan; odmerek so prilagajali tako, da je bila po 4 urah dosežena največja koncentracija natrijevega fondaparinuksata od 0,5 do 1 mg/l.
If PCI was performed, patients received either intravenous fondaparinux (fondaparinux patients) or weight adjusted intravenous UFH (enoxaparin patients) as adjunctive therapy, dependent on the timing of the last subcutaneous dose and planned use of GP IIb/IIIa inhibitor. 
Če je bila izvedena PCI, so bolniki dodatno intravensko prejeli bodisi fondaparinuks (bolniki, ki so prejemali fondaparinuks) bodisi nefrakcionirani heparin, prilagojen na telesno maso (bolniki, ki so prejemali enoksaparin), odvisno od časa zadnje aplikacije subkutanega odmerka in predvidene uporabe zaviralca GP IIb/IIIa.
The fondaparinux clinical program was designed to demonstrate the efficacy of fondaparinux for the prevention of venous thromboembolic events (VTE), i.e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery. 
Klinični program za fondaparinuks je bil zasnovan za dokazovanje učinkovitosti fondaparinuksa pri preprečevanju venskih trombemboličnih dogodkov (VTE), npr. proksimalne in distalne globoke venske tromboze (DVT) in pljučne embolije (PE), pri bolnikih po ortopedskih operacijah spodnjih okončin, kot je operacija zloma kolka, velike operacije kolen ali kirurška zamenjava kolka.
• swelling (oedema) 
• oteklina (edem);
In the Phase III study in STEMI patients, the most commonly reported non-bleeding adverse events (reported in at least 1% of subjects on fondaparinux) were atrial fibrillation, pyrexia, chest pain, headache, ventricular tachycardia, vomiting, and hypotension. 
V študiji III. faze pri bolnikih s STEMI so najpogosteje poročali o naslednjih neželenih učinkih, ki niso bili povezani s krvavitvami (poročila pri najmanj 1 % oseb, ki so prejemale fondaparinuks): atrijska fibrilacija, zvišana telesna temperatura, bolečina v prsih, glavobol, ventrikularna tahikardija, bruhanje in hipotenzija.
• The other ingredient(s) are sodium chloride, water for injections, and hydrochloric acid and/or sodium hydroxide to adjust the pH (see section 2). 
• Pomožne snovi so natrijev klorid, voda za injekcije in klorovodikova kislina in/ali natrijev hidroksid za uravnavanje pH (glejte poglavje 2).
• internal bleeding in the brain, liver or abdomen 
• notranja krvavitev v možganih, jetrih ali trebuhu;
The adverse event profile reported in the ACS program is consistent with the adverse drug reactions identified for VTE prophylaxis. 
Profil neželenih učinkov o katerem so poročali med programom akutnega koronarnega sindroma je konsistenten z neželenimi učinki zdravila, ugotovljenimi pri preprečevanju VTE.
As renal function is generally decreasing with age, elderly patients may show reduced elimination and increased exposure of fondaparinux (see section 5.2). 
Ledvična funkcija s starostjo na splošno upada, zato je lahko pri starejših bolnikih zmanjšano izločanje in povečana izpostavljenost fondaparinuksu (glejte poglavje 5.2).
• Treatment of superficial-vein thrombosis - The safety and efficacy of fondaparinux in patients with severe hepatic impairment has not been studied, therefore fondaparinux is not recommended for use in these patients (see section 4.4). 
• Zdravljenje povrhnje venske tromboze - Varnost in učinkovitost fondaparinuksa pri bolnikih s hudo okvaro jeter nista raziskani, zato ga pri takšnih bolnikih ni priporočljivo uporabljati (glejte poglavje 4.4).
The effects on the incidence of MI and RI were not statistically different between the fondaparinux and enoxaparin treatment groups. 
Učinka fondaparinuksa in enoksaparina na pojavnost MI in RI se med skupinama nista statistično pomembno razlikovala.
One experienced hypertensive encephalopathy accompanied by intracranial bleeding on day 5 of therapy resulting in fondaparinux discontinuation. 
Enemu bolniku se je pojavila hipertenzivna encefalopatija, ki jo je spremljala intrakranialna krvavitev, 5. dan zdravljenja in je povzročila prekinitev uporabe fondaparinuksa.
Uncommon: anaemia, thrombocytopaenia 
Občasni: anemija, trombocitopenija
Treatment with fondaparinux was demonstrated to be non-inferior to unfractionated heparin (VTE rates 3.8% and 5.0%, respectively). 
Dokazali so, da zdravljenje s fondaparinuksom ni bilo slabše od nefrakcioniranega heparina (pogostosti VTE 3,8 % oziroma 5,0 %).
• prevent the formation of blood clots in the blood vessels of the legs or lungs after orthopaedic surgery (such as hip or knee surgery) or abdominal surgery 
• preprečevanje tvorbe krvnih strdkov v žilah nog ali pljuč po ortopedskih operacijah (kot so operacije kolka ali kolen) ali po operacijah v trebušni votlini;
Fondaparinux should be used with caution in patients who have an increased risk of haemorrhage, such as those with congenital or acquired bleeding disorders (e.g. platelet count <50,000/mm3), active ulcerative gastrointestinal disease and recent intracranial haemorrhage or shortly after brain, spinal or ophthalmic surgery and in special patient groups as outlined below. 
Fondaparinuks moramo uporabljati previdno pri bolnikih s povečanim tveganjem za krvavitev, kot so bolniki s prirojenimi ali pridobljenimi motnjami strjevanja krvi (npr. število trombocitov < 50.000/mm3), bolniki z aktivno ulcerativno gastrointestinalno boleznijo, bolniki po nedavni intrakranialni krvavitvi, bolniki, ki so bili pred kratkim operirani na možganih, hrbtenici ali očeh, in zgoraj navedene posebne skupine bolnikov.
In studies versus enoxaparin 40 mg once daily started 12 hours before surgery, major bleeding was observed in 2.8% of fondaparinux patients treated with the recommended dose, compared to 2.6% with enoxaparin. 
V preskušanjih fondaparinuksa v primerjavi s 40 mg enoksaparina enkrat na dan s pričetkom 12 ur pred operacijo so opazili v skupini bolnikov, ki je prejemala fondaparinuks v priporočenem odmerku, 2,8 % velikih krvavitev v primerjavi z 2,6 % v skupini bolnikov z enoksaparinom.
In severe renal impairment (creatinine clearance < 30 ml/min), plasma clearance is approximately 5 times lower than in normal renal function. 
Pri hudi okvari delovanja ledvic (kreatininski očistek < 30 ml/min), je plazemski očistek približno 5-krat manjši kot pri normalnem delovanju ledvic.
Minor gastrointestinal bleeding was reported in another patient on day 5 of therapy which resulted in temporary discontinuation of fondaparinux. 
Pri drugem bolniku so 5. dan zdravljenja zabeležili manjšo gastrointestinalno krvavitev, ki je povzročila začasno prekinitev uporabe fondaparinuksa.
Do not throw away any medicines or syringes via wastewater or household waste. 
Zdravila in injekcijskih brizg ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
Fondaparinux provided a significant reduction in the overall rate of VTE compared with placebo [3 patients (1.4%) vs 77 patients (35%), respectively]. 
Fondaparinuks je dosegel pomembno zmanjšanje celokupnega deleža VTE v primerjavi s placebom [3 bolniki (1,4 %) vs 77 bolnikov (35 %)].
Incidence 
Incidenca
Fondaparinux significantly reduced the overall rate of VTE compared to placebo [18 patients (5.6%) vs 34 patients (10.5%), respectively]. 
Fondaparinuks je signifikantno zmanjšal celotno incidenco VTE v primerjavi s placebom [18 bolnikov (5,6 %) proti 34 bolnikom (10,5 %)].
In UA/NSTEMI and STEMI patients undergoing non-primary PCI, the use of fondaparinux as the sole anticoagulant during PCI is not recommended due to an increased risk of guiding catheter thrombus (see clinical studies section 5.1). 
Pri bolnikih z nestabilno angino pektoris/NSTEMI in STEMI, pri katerih bo opravljena neprimarna PCI, med PCI ni priporočljivo uporabljati fondaparinuksa kot edinega antigoagulanta, ker obstaja večje tveganje za pojav tromba na vodilnem katetru (glejte Klinične študije, poglavje 5.1).
Intravenous administration should be through an existing intravenous line either directly or using a small volume (25 or 50ml) 0.9% saline minibag. 
Pri intravenski aplikaciji je treba zdravilo aplicirati preko obstoječe intravenske linije, bodisi neposredno bodisi v manjšem volumnu 0,9 % fiziološke raztopine (25 ali 50 ml) v minibagu.
• reduction in potassium in your blood. 
• zmanjšanje vrednosti kalija v krvi.
Incidences of bleeding events in patients receiving the recommended regimen in the treatment of DVT or PE with normal renal function, mild renal impairment, moderate renal impairment and severe renal impairment were 3.0 % (34/1,132), 4.4 % (32/733), 6.6% (21/318), and 14.5 % (8/55) respectively. 
Incidence krvavitev pri bolnikih, ki so prejemali priporočeno shemo za zdravljenje DVT ali PE in so imeli normalno ledvično funkcijo, blago ledvično okvaro, zmerno ledvično okvaro oziroma hudo ledvično okvaro, so bile 3,0 % (34/1132), 4,4 % (32/733), 6,6 % (21/318) oziroma 14,5 % (8/55).
The active substance is: 
Zdravilna učinkovina je:
The mean treatment duration was 5.5 days in the fondaparinux group and 5.2 days in the enoxaparin group. 
V skupini, ki je prejemala fondaparinuks, je zdravljenje v povprečju trajalo 5,5 dni, v skupini, ki je prejemala enoksaparin pa 5,2 dni.
Patients eligible for fondaparinux 2.5 mg treatment should have acute, symptomatic, isolated, spontaneous superficial-vein thrombosis of the lower limbs, at least 5 cm long and documented by ultrasonographic investigation or other objective methods. 
Bolniki, primerni za zdravljenje z 2,5 mg fondaparinuksa so tisti, ki imajo akutno, simptomatsko, izolirano spontano povrhnjo vensko trombozo spodnjih udov, dolgo vsaj 5 cm in potrjeno z ultrazvočnim pregledom ali drugimi objektivnimi metodami.
Fondaparinux neither influenced the INR activity of warfarin, nor the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the pharmacokinetics of digoxin at steady state. 
Fondaparinuks ni vplival niti na INR aktivnost varfarina, niti na čas krvavitve med zdravljenjem z acetilsalicilno kislino ali piroksikamom, niti na farmakokinetiko digoksina v stanju dinamičnega ravnovesja.
The incidence of symptomatic VTE, including PE was not significantly different between treatment groups. 
Pogostnost simptomatskih venskih trombemboličnih dogodkov (VTE), vključno s pljučno embolijo (PE), se ni pomembno razlikovala med obema skupinama zdravil.
Paediatric population - Fondaparinux is not recommended for use in children below 17 years of age due to a lack of data on safety and efficacy (see sections 5.1 and 5.2). 
Otroci - Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba fondaparinuksa pri otrocih, mlajših od 17 let, ni priporočljiva (glejte poglavji 5.1 in 5.2).
• internal bleeding in the brain or abdomen 
• notranja krvavitev v možganih ali trebuhu;
Major bleedings, all at surgical site and none fatal, were observed in 8 patients (2.4%) treated with fondaparinux 2.5 mg compared to 2 (0.6%) with placebo. 
Velike krvavitve, vse na mestu kirurške rane in nobene s smrtnim izidom so opazili pri 8 bolnikih (2,4 %), ki so prejemali fondaparinuks 2,5 mg v primerjavi z 2 bolnikoma (0,6 %), ki sta prejemala placebo.
Hepatic impairment - Following a single, subcutaneous dose of fondaparinux in subjects with moderate hepatic impairment (Child-Pugh Category B), total (i.e., bound and unbound) Cmax and AUC were decreased by 22% and 39%, respectively, as compared to subjects with normal liver function. 
Jetrna okvara - Po enkratnem subkutanem odmerku fondaparinuksa se je pri osebah z zmerno okvaro jeter (kategorija B po Child-Pugh-u) skupna (to je vezanega in prostega) vrednost Cmax in AUC zmanjšala, in sicer Cmax za 22 %, AUC pa za 39 % v primerjavi z osebami z normalnim delovanjem jeter.
The solution is a clear and colourless liquid. 
Raztopina je bistra in brezbarvna tekočina.
• Prevention of VTE - Patients with body weight <50 kg are at increased risk of bleeding. 
• Preprečevanje VTE - Bolniki s telesno maso < 50 kg imajo povečano tveganje za krvavitev.
• Prevention of VTE and Treatment of UA/NSTEMI and STEMI - Dosing adjustment of fondaparinux is not necessary. 
• Preprečevanje VTE in zdravljenje UA/NSTEMI in STEMI - Prilagajanje odmerka ni potrebno.
Children and adolescents Arixtra has not been tested in children and adolescents under the age of 17 years. 
Pri otrocih in mladostnikih, mlajših od 17 let, uporabe zdravila Arixtra niso raziskovali.
Treatment of unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI) in patients who underwent subsequent PCI with adjunctive UFH 
Zdravljenje nestabilne angine pektoris (UA) in miokardnega infarkta brez dviga segmenta ST (NSTEMI) pri bolnikih, ki so imeli opravljeno poznejšo PCI z dodatkom UFH
There are limited clinical data available from patients with creatinine clearance less than 30 ml/min. 
Pri bolnikih s kreatininskim očistkom, manjšim od 30 ml/min, so na voljo le omejeni klinični podatki.
• increase in bilirubin (a substance produced by the liver) in the blood 
• povečanje vrednosti bilirubina (snovi, ki nastaja v jetrih) v krvi.
Adverse reactions in patients treated for VTE1 
Neželeni učinki pri bolnikih, ki so se zdravili zaradi venske trombembolije (VTE)1
Breast-feeding is not recommended during treatment with Arixtra. 
Med zdravljenjem z zdravilom Arixtra dojenje ni priporočljivo.
The recommended dose of fondaparinux is 7.5 mg (patients with body weight ≥ 50, ≤ 100kg) once daily administered by subcutaneous injection. 
Priporočeni odmerek fondaparinuksa je 7,5 mg (bolniki s telesno maso ≥ 50, ≤ 100 kg) enkrat na dan, apliciran s subkutano injekcijo.
Fondaparinux is contra-indicated in severe renal impairment (creatinine clearance <30 ml/min) and should be used with caution in patients with moderate renal impairment (creatinine clearance 30-50 ml/min). 
Fondaparinuks je pri hudih ledvičnih okvarah (očistek kreatinina < 30 ml/min) kontraindiciran, pri bolnikih z zmernimi ledvičnimi okvarami (očistek kreatinina 30-50 ml/min) pa ga je treba uporabljati previdno.
Breast-feeding is not recommended during treatment with fondaparinux. 
Med zdravljenjem s fondaparinuksom se dojenja ne priporoča.
• Prevention of VTE - Dosing adjustment of fondaparinux is not necessary. 
• Preprečevanje VTE - Prilagajanje odmerka ni potrebno.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: 
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom:
The incidence of symptomatic DVT was similar between treatment groups: 6 patients (0.4%) in the fondaparinux group vs 5 patients (0.3%) in the dalteparin group. 
Pojavnost simptomatske globoke venske tromboze je bila v obeh skupinah podobna: pojavila se je pri 6 bolnikih (0,4 %), ki so prejemali fondaparinuks in 5 bolnikih (0,3 %), ki so prejemali dalteparin.